Business Wire

Dr. Reddy's Laboratories Announces the Launch of Testosterone Gel, 1.62% (20.25 mg/1.25 g Pump Actuation) in the U.S. Market

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today ...
Monthly Prescribing Reference

AndroGel 1.62% Approved for Hypogonadism

The FDA has approved AndroGel (testosterone gel; Abbott) 1.62% for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone, including ...
FiercePharma

Abbott Receives U.S. FDA Approval for AndroGel® 1.62% to Treat Men with Low Testosterone

ABBOTT PARK, Ill., April 29, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) has approved AndroGel® (testosterone gel) 1.62%, a clear, odorless ...
FierceBiotech

Endo Pharmaceuticals Receives FDA Approval for FORTESTA(TM) (Testosterone) Gel as a Class III Product for Topical Use for Men wi

Endo Pharmaceuticals Receives FDA Approval for FORTESTA(TM) (Testosterone) Gel as a Class III Product for Topical Use for Men with Low Testosterone FORTESTA Gel is the first approved testosterone ...
Healio

New testosterone therapies offer options for men with hypogonadism

Please provide your email address to receive an email when new articles are posted on . NEW ORLEANS — Three new testosterone therapies offer innovative drug delivery options for men with hypogonadism ...
Healio

FDA approves testosterone gel for hypogonadism

Please provide your email address to receive an email when new articles are posted on . The FDA has approved a clear, odorless gel for the treatment of hypogonadism. According to a company press ...